Colon cancer is the second leading cause of cancer deaths in the U.S., and a new study shows it may also raise the risk of ...

A new smart liner called Roliner lets amputees adjust prosthetic fit in real time via smartphone, easing pain and improving ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...